Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Stem Cell Research
Osiris Therapeutics Announces $20 million Private Placement
June 26th, 2007
Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company announced today that it had priced a private placement of its common stock through the efforts of Friedli Corporate Finance, Inc. of Switzerland. The Company agreed to sell 1,757,469 shares, or $20 million, of its common stock at $11.38 per share, pursuant to a private placement intended to comply with Regulation S of the Securities Act of 1933. The common stock will be sold directly to institutional and accredited investors primarily based in Switzerland, and will result in cash proceeds of approximately $20 million. There were no commissions paid on the proceeds raised. The placement was...
Source: Drug Law Weekly (2007-06-26)
|
